Search

Your search keyword '"Symmons, Deborah P. M."' showing total 557 results
Start Over Author "Symmons, Deborah P. M."
557 results on '"Symmons, Deborah P. M."'

5. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Author

Mercer, Louise K, Galloway, James B, Lunt, Mark, Davies, Rebecca, Low, Audrey L S, Dixon, William G, Watson, Kath D, Symmons, Deborah P M, Hyrich, Kimme L, Maiden, Nicola, Price, Tom, Hopkinson, Neil, OʼReilly, Sheila, Hordon, Lesley, Griffiths, Ian, Porter, Duncan, Madhok, R, Hassell, Andy, Cooper, R G, Choy, Ernest, Walsh, David, Emery, Professor Paul, Knight, Susan, Bruce, Ian, Taggart, Allister, Scott, Professor David, Thompson, Paul, McCrae, Fiona, Goodfellow, Rhian, Kitas, Professor George, Jubb, Ronald, Abernethy, Rikki, Green, Sandra, Sanders, Paul, Coulson, Amanda, Harrison, Bev, Bukhari, Marwan, and Klimiuk, Peter

Published
2017
Full Text
View/download PDF

12. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Author

Mercer, Louise K, Lunt, Mark, Low, Audrey L S, Dixon, William G, Watson, Kath D, Symmons, Deborah P M, Hyrich, Kimme L, Maiden, Nicola, Price, Tom, Hopkinson, Neil, OʼReilly, Sheila, Hordon, Lesley, Griffiths, Ian, Porter, Duncan, Madhok, R, Hassell, Andy, Cooper, R G, Choy, Ernest, Walsh, David, Emery, Paul, Knight, Susan, Bruce, Ian, Taggart, Allister, Scott, David, Thompson, Paul, McCrae, Fiona, Goodfellow, Rhian, Kitas, George, Jubb, Ronald, Abernethy, Rikki, Green, Sandra, Sanders, Paul, Coulson, Amanda, Harrison, Bev, Bukhari, Marwan, and Klimiuk, Peter

Published
2015
Full Text
View/download PDF

19. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

Author

Burton, Paul R., Clayton, David G., Cardon, Lon R., Craddock, Nick, Deloukas, Panos, Duncanson, Audrey, Kwiatkowski, Dominic P., McCarthy, Mark I., Ouwehand, Willem H., Samani, Nilesh J., Todd, John A., Donnelly, Peter, Barrett, Jeffrey C., Davison, Dan, Easton, Doug, Evans, David, Leung, Hin-Tak, Marchini, Jonathan L., Morris, Andrew P., Spencer, Chris C. A., Tobin, Martin D., Attwood, Antony P., Boorman, James P., Cant, Barbara, Everson, Ursula, Hussey, Judith M., Jolley, Jennifer D., Knight, Alexandra S., Koch, Kerstin, Meech, Elizabeth, Nutland, Sarah, Prowse, Christopher V., Stevens, Helen E., Taylor, Niall C., Walters, Graham R., Walker, Neil M., Watkins, Nicholas A., Winzer, Thilo, Jones, Richard W., McArdle, Wendy L., Ring, Susan M., Strachan, David P., Pembrey, Marcus, Breen, Gerome, St Clair, David, Caesar, Sian, Gordon-Smith, Katherine, Jones, Lisa, Fraser, Christine, Green, Elaine K., Grozeva, Detelina, Hamshere, Marian L., Holmans, Peter A., Jones, Ian R., Kirov, George, Moskvina, Valentina, Nikolov, Ivan, O'Donovan, Michael C., Owen, Michael J., Collier, David A., Elkin, Amanda, Farmer, Anne, Williamson, Richard, McGuffin, Peter, Young, Allan H., Ferrier, I. Nicol, Ball, Stephen G., Balmforth, Anthony J., Barrett, Jennifer H., Bishop, D. Timothy, Iles, Mark M., Maqbool, Azhar, Yuldasheva, Nadira, Hall, Alistair S., Braund, Peter S., Dixon, Richard J., Mangino, Massimo, Stevens, Suzanne, Thompson, John R., Bredin, Francesca, Tremelling, Mark, Parkes, Miles, Drummond, Hazel, Lees, Charles W., Nimmo, Elaine R., Satsangi, Jack, Fisher, Sheila A., Forbes, Alastair, Lewis, Cathryn M., Onnie, Clive M., Prescott, Natalie J., Sanderson, Jeremy, Mathew, Christopher G., Barbour, Jamie, Mohiuddin, M. Khalid, Todhunter, Catherine E., Mansfield, John C., Ahmad, Tariq, Cummings, Fraser R., Jewell, Derek P., Webster, John, Brown, Morris J., Lathrop, G. Mark, Connell, John, Dominiczak, Anna, Marcano, Carolina A. Braga, Burke, Beverley, Dobson, Richard, Gungadoo, Johannie, Lee, Kate L., Munroe, Patricia B., Newhouse, Stephen J., Onipinla, Abiodun, Wallace, Chris, Xue, Mingzhan, Caulfield, Mark, Farrall, Martin, Barton, Anne, Bruce, Ian N., Donovan, Hannah, Eyre, Steve, Gilbert, Paul D., Hider, Samantha L., Hinks, Anne M., John, Sally L., Potter, Catherine, Silman, Alan J., Symmons, Deborah P. M., Thomson, Wendy, Worthington, Jane, Dunger, David B., Widmer, Barry, Frayling, Timothy M., Freathy, Rachel M., Lango, Hana, Perry, John R. B., Shields, Beverley M., Weedon, Michael N., Hattersley, Andrew T., Hitman, Graham A., Walker, Mark, Elliott, Kate S., Groves, Christopher J., Lindgren, Cecilia M., Rayner, Nigel W., Timpson, Nicholas J., Zeggini, Eleftheria, Newport, Melanie, Sirugo, Giorgio, Lyons, Emily, Vannberg, Fredrik, Hill, Adrian V. S., Bradbury, Linda A., Farrar, Claire, Pointon, Jennifer J., Wordsworth, Paul, Brown, Matthew A., Franklyn, Jayne A., Heward, Joanne M., Simmonds, Matthew J., Gough, Stephen C. L., Seal, Sheila, Stratton, Michael R., Rahman, Nazneen, Ban, Maria, Goris, An, Sawcer, Stephen J., Compston, Alastair, Conway, David, Jallow, Muminatou, Rockett, Kirk A., Bumpstead, Suzannah J., Chaney, Amy, Downes, Kate, Ghori, Mohammed J. R., Gwilliam, Rhian, Hunt, Sarah E., Inouye, Michael, Keniry, Andrew, King, Emma, McGinnis, Ralph, Potter, Simon, Ravindrarajah, Rathi, Whittaker, Pamela, Widden, Claire, Withers, David, Cardin, Niall J., Ferreira, Teresa, Pereira-Gale, Joanne, Hallgrimsdottir, Ingileif B., Howie, Bryan N., Su, Zhan, Teo, Yik Ying, Vukcevic, Damjan, Bentley, David, and Compston, Alistair

Subjects
Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Author(s): The Wellcome Trust Case Control Consortium; Management Committee; Paul R. Burton [1]; David G. Clayton [2]; Lon R. Cardon [3]; Nick Craddock [4]; Panos Deloukas [5]; Audrey Duncanson [6]; [...]

Published
2007
Full Text
View/download PDF

21. Long-term persistence with rituximab in patients with rheumatoid arthritis

Author

Oldroyd, Alexander G S, Symmons, Deborah P M, Sergeant, Jamie C, Kearsley-Fleet, Lianne, Watson, Kath, Lunt, Mark, and Hyrich, Kimme L

Subjects
rheumatoid arthritis, Male, Time Factors, DMARDs (biologic), Clinical Science, Middle Aged, United Kingdom, Arthritis, Rheumatoid, Survival Rate, Treatment Outcome, biological therapies, Humans, Immunologic Factors, epidemiology, Female, Prospective Studies, Registries, pharmacology, Rituximab, Aged, Follow-Up Studies
Abstract

Objectives To investigate the long term persistence of rituximab (RTX) in a large observational RA cohort, investigate persistence of RTX when used as a first or second line biologic DMARD (bDMARD), to characterize subsequent bDMARD treatment following RTX. Methods Patients with RA starting treatment with RTX (MabThera) between 2008 and 2011 were recruited into the British Society for Rheumatology Biologics Register for RA. Duration of RTX treatment over the first 4 years after initiation was estimated via Kaplan-Meier estimates and the reason for discontinuation was ascertained. Subsequent bDMARD use following RTX discontinuation was characterised. Treatment survival in bDMARD-naïve (first line RTX use) and experienced (second line RTX use) cohorts was described. Results One thousand six hundred and twenty-nine patients were recruited (1371 bDMARD-experienced and 258 bDMARD-naïve). Sixty percent of the whole cohort remained on RTX after 4 years. Ineffectiveness (46%) and death (24%) were the most common reason for RTX discontinuation. RTX discontinuation was associated with RF negativity for the bDMARD-experienced cohort. Of those that discontinued RTX, 46% initiated treatment with another bDMARD, with tocilizumab being the most common. Conclusion This large study of patients initiating RTX treatment for severe RA found that 60% persisted with treatment after 4 years. This study also identified that RTX is tolerated well when used as a first or second line bDMARD.

Published
2018

27. Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK

Author

Davies, Rebecca, Dixon, William G, Watson, Kath D, Lunt, Mark, Symmons, Deborah P M, Hyrich, Kimme L, Maiden, Nicola, Price, Tom, Hopkinson, Neil, OʼReilly, Sheila, Hordon, Lesley, Griffiths, Ian, Porter, Duncan, Capell, Hilary, Hassell, Andy, Benitha, Romela, Choy, Ernest, Walsh, David, Emery, Paul, Knight, Susan, Bruce, Ian, Taggart, Allister, Scott, David, Thompson, Paul, McCrae, Fiona, Goodfellow, Rhian, Kitas, George, Jubb, Ronald, Abernethy, Rikki, Clarke, Shane, Green, Sandra, Sanders, Paul, Coulson, Amanda, Harrison, Bev, Bukhari, Marwan, and Klimiuk, Peter

Published
2013
Full Text
View/download PDF

40. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

Author

Galloway, James B., Hyrich, Kimme L., Mercer, Louise K., Dixon, William G., Fu, Bo, Ustianowski, Andrew P., Watson, Kath D., Lunt, Mark, and Symmons, Deborah P. M.

Published
2011
Full Text
View/download PDF

43. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls

Author

Craddock, Nick, Hurles, Matthew E., Cardin, Niall, Pearson, Richard D., Plagnol, Vincent, Robson, Samuel, Vukcevic, Damjan, Barnes, Chris, Conrad, Donald F., Giannoulatou, Eleni, Holmes, Chris, Marchini, Jonathan L., Stirrups, Kathy, Tobin, Martin D., Wain, Louise V., Yau, Chris, Aerts, Jan, Ahmad, Tariq, Daniel Andrews, T., Arbury, Hazel, Attwood, Anthony, Auton, Adam, Ball, Stephen G., Balmforth, Anthony J., Barrett, Jeffrey C., Barroso, Inês, Barton, Anne, Bennett, Amanda J., Bhaskar, Sanjeev, Blaszczyk, Katarzyna, Bowes, John, Brand, Oliver J., Braund, Peter S., Bredin, Francesca, Breen, Gerome, Brown, Morris J., Bruce, Ian N., Bull, Jaswinder, Burren, Oliver S., Burton, John, Byrnes, Jake, Caesar, Sian, Clee, Chris M., Coffey, Alison J., Connell, John M. C., Cooper, Jason D., Dominiczak, Anna F., Downes, Kate, Drummond, Hazel E., Dudakia, Darshna, Dunham, Andrew, Ebbs, Bernadette, Eccles, Diana, Edkins, Sarah, Edwards, Cathryn, Elliot, Anna, Emery, Paul, Evans, David M., Evans, Gareth, Eyre, Steve, Farmer, Anne, Nicol Ferrier, I., Feuk, Lars, Fitzgerald, Tomas, Flynn, Edward, Forbes, Alistair, Forty, Liz, Franklyn, Jayne A., Freathy, Rachel M., Gibbs, Polly, Gilbert, Paul, Gokumen, Omer, Gordon-Smith, Katherine, Gray, Emma, Green, Elaine, Groves, Chris J., Grozeva, Detelina, Gwilliam, Rhian, Hall, Anita, Hammond, Naomi, Hardy, Matt, Harrison, Pile, Hassanali, Neelam, Hebaishi, Husam, Hines, Sarah, Hinks, Anne, Hitman, Graham A, Hocking, Lynne, Howard, Eleanor, Howard, Philip, Howson, Joanna M. M., Hughes, Debbie, Hunt, Sarah, Isaacs, John D., Jain, Mahim, Jewell, Derek P., Johnson, Toby, Jolley, Jennifer D., Jones, Ian R., Jones, Lisa A., Kirov, George, Langford, Cordelia F., Lango-Allen, Hana, Mark Lathrop, G., Lee, James, Lee, Kate L., Lees, Charlie, Lewis, Kevin, Lindgren, Cecilia M., Maisuria-Armer, Meeta, Maller, Julian, Mansfield, John, Martin, Paul, Massey, Dunecan C. O., McArdle, Wendy L., McGuffin, Peter, McLay, Kirsten E., Mentzer, Alex, Mimmack, Michael L., Morgan, Ann E., Morris, Andrew P., Mowat, Craig, Myers, Simon, Newman, William, Nimmo, Elaine R., O’Donovan, Michael C., Onipinla, Abiodun, Onyiah, Ifejinelo, Ovington, Nigel R., Owen, Michael J., Palin, Kimmo, Parnell, Kirstie, Pernet, David, Perry, John R. B., Phillips, Anne, Pinto, Dalila, Prescott, Natalie J., Prokopenko, Inga, Quail, Michael A., Rafelt, Suzanne, Rayner, Nigel W., Redon, Richard, Reid, David M., Renwick, Anthony, Ring, Susan M., Robertson, Neil, Russell, Ellie, St Clair, David, Sambrook, Jennifer G., Sanderson, Jeremy D., Schuilenburg, Helen, Scott, Carol E., Scott, Richard, Seal, Sheila, Shaw-Hawkins, Sue, Shields, Beverley M., Simmonds, Matthew J., Smyth, Debbie J., Somaskantharajah, Elilan, Spanova, Katarina, Steer, Sophia, Stephens, Jonathan, Stevens, Helen E., Stone, Millicent A., Su, Zhan, Symmons, Deborah P. M., Thompson, John R., Thomson, Wendy, Travers, Mary E., Turnbull, Clare, Valsesia, Armand, Walker, Mark, Walker, Neil M., Wallace, Chris, Warren-Perry, Margaret, Watkins, Nicholas A., Webster, John, Weedon, Michael N., Wilson, Anthony G., Woodburn, Matthew, Wordsworth, Paul B., Young, Allan H., Zeggini, Eleftheria, Carter, Nigel P., Frayling, Timothy M., Lee, Charles, McVean, Gil, Munroe, Patricia B., Palotie, Aarno, Sawcer, Stephen J., Scherer, Stephen W., Strachan, David P., Tyler-Smith, Chris, Brown, Matthew A., Burton, Paul R., Caulfield, Mark J., Compston, Alastair, Farrall, Martin, Gough, Stephen C. L., Hall, Alistair S., Hattersley, Andrew T., Hill, Adrian V. S., Mathew, Christopher G., Pembrey, Marcus, Satsangi, Jack, Stratton, Michael R., Worthington, Jane, Deloukas, Panos, Duncanson, Audrey, Kwiatkowski, Dominic P., McCarthy, Mark I., Ouwehand, Willem H., Parkes, Miles, Rahman, Nazneen, Todd, John A., Samani, Nilesh J., and Donnelly, Peter

Published
2010
Full Text
View/download PDF

50. A multicenter, randomized, placebo‐controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis

Author

Kitas, George D., Nightingale, Peter, Armitage, Jane, Sattar, Naveed, Belch, Jill J. F., Symmons, Deborah P. M., Kitas, George, Belch, Jill, Symmons, Deborah, Williams, Hawys, Vasishta, Shobna, Storey, Rebecca, Bruce, Ian, Durrington, Paul, McInnes, Iain, Situnayake, Deva, Struthers, Allan, Lowe, Gordon, Fox, Keith, Haskard, Dorian, Dore, Caroline, Bosworth, Ailsa, Frenneaux, Michael, Edwards, Christopher, Emberson, Jonathan, Bax, Deborah, Cobbe, Stuart, Stott, David, Sturrock, Roger, Macfarlane, Peter, Klocke, Rainer, Pullar, Tom, Knight, Susan, Rowe, Iain, Kumar, Pradeep, Goodson, Nicky, Mulherin, Diarmuid, Brzeski, Micheal, Gardiner, Philip, Walker, David, Callaghan, Rob, Allen, Margaret, McCarey, David, George, Emmanuel, Deighton, Chris, Kirkham, Bruce, Teh, Lee‐Suan, Luqmani, Raashid, Chakravarty, Kuntal, Nixon, Jenny, Richards, Selwyn, Scott, David, Woolf, Tony, Prouse, Peter, Packham, Jonathan, Davies, Martin, DeLord, Denise, O’Neill, Terence, Pande, Ira, Harvie, John, Watts, Richard, Rankin, Elizabeth, Papasavvas, George, Emery, Paul, Sinha, Arvind, Dasgupta, Bhaskar, Creamer, Paul, Zoma, Asad, Walsh, David, Van‐Laar, Jaap, Capps, Nigel, Cairns, Andrew, Marguerie, Christopher, Kumar, Namita, Abernethy, Rikki, Lillicrap, Mark, Ralston, Stuart, Makadsi, Raad, Hopkinson, Neil, Tan, Su, Akil, Mohammed, Ahmad, Yasmeen, Adler, Matthew, Bukhari, Marwan, Sanders, Paul, Roussou, Euthalia, Binymin, Khalid, Hassan, Alaa, Hughes, Rod, O’Reilly, David, Sainsbury, Paul, Richmond, Ruth, Malgorzata, Magliano, Nisar, Mohammed, McEntergart, Ann, Roy, Dipak, Marks, Jeffrey, Batley, Michael, McKenna, Frank, Irani, Mike, Harris, Helen, Smyth, Anita, Tunn, Eddie, Young, Adam, Thomas, Joegi, Hall, Frances, Marshall, Tarnya, Rao, Chandini, Baburaj, Krishnan, Dixey, Josh, Gendi, Nagui, Birrell, Fraser, Chelliah, Gladstone, Morgan, Ann, Fishman, Daniel, Knights, Sally, Coady, David, Smith, Bill, Harrison, Beverley, Siebert, Stefan, Chan, Anthony, Putchakayala, Kiran, Al‐Ansari, Atheer, Gough, Andrew, Naz, Sophia, Pyne, Dev, Mahmud, Taher, Patel, Yusaf, and Isdale, Amanda

Abstract

Objective:\ud \ud Rheumatoid arthritis (RA) is associated with increased cardiovascular event (CVE) risk. The impact of statins in RA is not established. We assessed whether atorvastatin is superior to placebo for the primary prevention of CVEs in RA patients.\ud Methods:\ud \ud A randomized, double‐blind, placebo‐controlled trial was designed to detect a 32% CVE risk reduction based on an estimated 1.6% per annum event rate with 80% power at P < 0.05. RA patients age >50 years or with a disease duration of >10 years who did not have clinical atherosclerosis, diabetes, or myopathy received atorvastatin 40 mg daily or matching placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, transient ischemic attack, or any arterial revascularization. Secondary and tertiary end points included plasma lipids and safety.\ud Results:\ud \ud A total of 3,002 patients (mean age 61 years; 74% female) were followed up for a median of 2.51 years (interquartile range [IQR] 1.90, 3.49 years) (7,827 patient‐years). The study was terminated early due to a lower than expected event rate (0.70% per annum). Of the 1,504 patients receiving atorvastatin, 24 (1.6%) experienced a primary end point, compared with 36 (2.4%) of the 1,498 receiving placebo (hazard ratio [HR] 0.66 [95% confidence interval (95% CI) 0.39, 1.11]; P = 0.115 and adjusted HR 0.60 [95% CI 0.32, 1.15]; P = 0.127). At trial end, patients receiving atorvastatin had a mean ± SD low‐density lipoprotein (LDL) cholesterol level 0.77 ± 0.04 mmoles/liter lower than those receiving placebo (P < 0.0001). C‐reactive protein level was also significantly lower in the atorvastatin group than the placebo group (median 2.59 mg/liter [IQR 0.94, 6.08] versus 3.60 mg/liter [IQR 1.47, 7.49]; P < 0.0001). CVE risk reduction per mmole/liter reduction in LDL cholesterol was 42% (95% CI −14%, 70%). The rates of adverse events in the atorvastatin group (n = 298 [19.8%]) and placebo group (n = 292 [19.5%]) were similar.\ud Conclusion:\ud \ud Atorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholesterol level than placebo in patients with RA. The 34% CVE risk reduction is consistent with the Cholesterol Treatment Trialists’ Collaboration meta‐analysis of statin effects in other populations.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results